Pfizer, Inc. · NYSE:PFE
Pfizer — Investor Presentation (November 2006)
9 slides from Pfizer's investor presentation, Nov 30, 2006
Slide 1: Jeff Kindler, Chief Executive Officer
Jeff Kindler Chief Executive Officer 1 Valid as of November 30, 2006
Slide 2: Maximizing Current Performance
Maximizing Current Performance Maximizing current performance y Raising 2006 EPS guidance y Forecasting high single digit average annual adjusted diluted EPS growth in 2007-2008 over higher 2006 base y Lower, flexible cost structure Valid as of November 30, 2006
Slide 3: Strong Pipeline Momentum
Strong Pipeline Momentum Maximizing current performance Pipeline momentum for delivering steady stream of new products y Significant increase in Phase 3 pipeline by 2009 y Goal of four new internally-developed products per year starting 2011 y Diverse therapeutic areas, treatment modalities y Ta
Slide 4: Torcetrapib / Atorvastatin and CETP Portfolio
Torcetrapib / Atorvastatin and CETP Portfolio Maximizing current performance Pipeline momentum for delivering steady stream of new products Torcetrapib / Atorvastatin first in new therapeutic class y Cardiovascular disease: world’s #1 killer y CETP inhibition potential to redefine cardiovascul
Slide 5: Significant, Ongoing Productivity Gains
Significant, Ongoing Productivity Gains Maximizing current performance Pipeline momentum for delivering steady stream of new products Torcetrapib / Atorvastatin - first in new therapeutic class Measurable, sustainable R&D productivity improvements; more to come y Encouraging progress from fo
Slide 6: Collaborative Approach
Collaborative Approach Maximizing current performance Pipeline momentum for delivering steady stream of new products Torcetrapib / Atorvastatin: first in new therapeutic class Measurable, sustainable R&D productivity improvements; more to come Greater engagement with worldwide scientific c
Slide 7: Aggressive Approach to External Opportunities
Aggressive Approach to External Opportunities Maximizing current performance Pipeline momentum for delivering steady stream of new products Torcetrapib / Atorvastatin: first in new therapeutic class Measurable, sustainable R&D productivity improvements; more to come Greater engagement with
Slide 8: Realism, Transparency, Accountability
Realism, Transparency, Accountability Maximizing current performance Pipeline momentum for delivering steady stream of new products Torcetrapib / Atorvastatin: first in new therapeutic class Measurable, sustainable R&D productivity improvements; more to come Greater engagement with worldwi
Slide 9: What You Will Hear Today
What You Will Hear Today Maximizing current performance Pipeline momentum for delivering steady stream of new products Torcetrapib / Atorvastatin: first in new therapeutic class Measurable, sustainable R&D productivity improvements; more to come Greater engagement with worldwide scientific